Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska; Ewa Malecka-Wojciesko

doi:10.5114/pg.2026.160317

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures Instructions for authors Publication charge

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2026
vol. 21

Send email

Copy url:

abstract:

Letter to the Editor

Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska

¹

,

Ewa Malecka-Wojciesko

²

Department of Digestive Tract Diseases, Medical University of Lodz, Poland
Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Poland

Gastroenterology Rev 2026; 21 (1): 108–110

DOI: https://doi.org/10.5114/pg.2026.160317

Online publish date: 2026/03/06

View full text Get citation

PlumX metrics:

Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska 1 , Ewa Malecka-Wojciesko 2

Patrycja Szałwińska

¹

,

Ewa Malecka-Wojciesko

²